Shandong Jincheng Pharmaceutical Group (300233.SZ): The world's first HPV therapeutic vaccine VGX-3100 has been approved for Phase II clinical trials.

Shandong Jincheng Pharmaceutical Group (300233.SZ) disclosed progress in external investments and strategic cooperation, stating that on September 20, 2024, the company's invested fund's equity company Dongfang Lue received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, approving the Phase II clinical trial application for the globally first HPV therapeutic vaccine VGX-3100 developed jointly by Dongfang Lue and U.S.-based Inovio Pharmaceuticals, Inc. for HPV-16/18-related anal cancer precancerous lesions. The approval of the Phase II clinical trial application for HPV-16/18-related anal cancer precancerous lesions is another significant development after VGX-3100's approval for cervical cancer precancerous lesions clinical trials.